Liraglutide alters brain and kidney fluid regulation

A new study published in Science Advances reveals that weight loss and diabetes medications, specifically GLP-1 receptor agonists like liraglutide, alter the body's ability to manage fluids. Research led by Michael P. Greenwood at the University of Bristol indicates that these drugs disrupt the biological chain responsible for water conservation.

The medication lowers levels of arginine vasopressin, a key hormone produced in the brain and stored in the pituitary gland. This hormone normally signals the kidneys to reabsorb water into the bloodstream; however, liraglutide reduces its presence, leading to increased water and sodium loss through urine.

In studies involving healthy adults and animal models, researchers observed that the drug shifts fluid intake patterns and reduces levels of copeptin, a secondary marker of hydration regulation. These findings provide a biological explanation for common side effects such as dehydration, nausea, and diarrhea, highlighting why patients are frequently advised to increase fluid intake while using these treatments.